Abstract
The breakthrough addition of pertuzumab or neratinib to established trastuzumab and chemotherapy for HER-2 positive breast cancer represent a new clinical success increasing cure rates for resectable tumors and transforming metastatic cancer disease into chronic disease. New research focuses on reducing acquired resistance. The integration of molecular classification of breast cancer according ER, PR and HER2 status into patient subgroups with crucial prognosis and treatment decision making revolutionizes cancer therapy. Combination of classical clinico-pathologic characteristics (age, histological grade, TNM stage) with molecular markers towards personalized treatment of women with breast cancer are improving relapse free and overall survival rates.
(Citation: Gastric & Breast Cancer
2019; 14(1): 28-32).
|
